11-dehydro-thromboxane-b2 and Nephrotic-Syndrome

In order to examine the intracellular thromboxane A2 (TXA2) signal transduction system in platelets of patients with nephrotic syndrome, we measured the levels of TXA2 metabolites in urine and blood and platelet calcium ion level as a result of STA2, an analog of STA2 (9,11-dimethylmethano-11,12-methano-TXA2) stimulation, and obtained the following results: (1) In pediatric patients with nephrotic syndrome, urinary thromboxane B2 (TXB2) and 11-dehydro-TXB2 excretion were signficantly higher in the onset and relapse groups compared to the remission and control groups. (2) The blood 11-dehydro-TXB2 level in the onset group was significantly higher than those in the remission and control groups. (3) Platelet calcium concentrations due to STA2 stimulation were significantly increased in the onset, relapse and remission groups compared to the control group. These findings suggest activation of the TXA2 signal transduction system in platelets of pediatric patients with nephrotic syndrome.

Topics: Blood Platelets; Calcium; Child; Child, Preschool; Female; Humans; Male; Nephrotic Syndrome; Thromboxane A2; Thromboxane B2

For the purpose of clarifying the changes occurring in thromboxane (TX)A2 metabolism in the platelet of nephrosis patients, we investigated the changes in platelet sensitivity to TXA2 and the changes in TXA2 production in pediatric patients with nephrotic syndrome (N.S.) using STA2 which is an analogue of TXA2 and ONO 3708 which is a TXA2 receptor antagonist. The subjects investigated in the present study consisted of 11 cases with initial onset of N.S. (onset group), 15 relapse patients (relapse group) and 15 children with N.S. without any recurrence in the past 6 months (remission group) as well as 25 normal children (control group). The results were as follows: (1) Platelet aggregation attributable to STA2 stimulation was enhanced at the onset and relapse of N.S. (2) Sensitivity to TXA2 was enhanced in the platelets of patients in the relapse group. (3) Though some demonstrated enhanced platelet sensitivity to TXA2, while others in the onset group did not, enhanced sensitivity was observed in all the patients along with an improvement in hypoalbuminemia. (4) The amount of daily urinary excretion of TXB2 and 11-dehydro-TXB2 in the onset group and relapse group was increased in comparison with the status in the remission group and control group. The above results demonstrated enhanced platelet sensitivity to TXA2 and increased biological production of TXA2 in patients with N.S., suggesting that TXA2 metabolism in the platelet is deeply involved in the pathophysiology of N.S.

Topics: Adolescent; Blood Platelets; Child; Child, Preschool; Female; Humans; Male; Nephrotic Syndrome; Platelet Aggregation; Recurrence; Serum Albumin; Thromboxane A2; Thromboxane B2